A single-arm phase 2 trial of mostly IDHwt GBM included 10 patients with IDHmut glioma, who had 70% progression-free survival after 6 months (PFS6) on panobinostat and the VEGF-A inhibitor bevacizumab, versus less than 30% PFS6 in IDHwt patients with GBM (49). This evidence concerns the gene VEGFA and glioma.